Skip to main navigation Skip to main content
info(at)avldigital.remove-this.de
Deutsch English
Narrow Search
Search narrowed by
Last searches

Results for *

Displaying results 1 to 1 of 1.

  1. Stammzellen - iPS-Zellen - Genomeditierung. Stem Cells - iPS Cells - Genome Editing =
    Stem cells - iPS cells - genome editing /
    Contributor: Müller, Susanne.; Rosenau, Henning.
    Published: 2018.
    Publisher:  Nomos Verlagsgesellschaft,, Baden-Baden :

    Location:
    Hochschule der Polizei des Landes Brandenburg, Hochschulbibliothek
    Inter-library loan:
    Unlimited inter-library loan, copies and loan
    Export to reference management software   RIS file
      BibTeX file
    Content information
    Source: Union catalogues
    Contributor: Müller, Susanne.; Rosenau, Henning.
    Media type: Ebook
    Format: Online
    ISBN: 9783845291901; 3845291907
    Series: Schriften zum Bio-, Gesundheits- und Medizinrecht ; ; v. 34
    Subjects: Regenerative medicine; Stem cells; Gene editing; Médecine régénératrice; Cellules souches; Édition génique; HEALTH & FITNESS; MEDICAL; MEDICAL; MEDICAL; MEDICAL; Gene editing; Regenerative medicine; Stem cells
    Scope: 1 online resource (366 pages)
    Notes:

    E. Why an "Ethics Exceptionalism" Approach May No Longer Be Justified.

    Cover; I. Stammzellen und iPS-Zellen; Grundlagen und Anwendung der Reprogrammierung adulter Zellen zu induzierten pluripotenten Stammzellen (iPSZ); Die geschichtliche Entwicklung der Reprogrammierung; Methoden der Reprogrammierung; Auswahl der Donor-/Ausgangszellen; Wahl der Reprogrammierungsfaktoren; Einschleusung der Faktoren; Phasen der Reprogrammierung; Initiation; Reifung; Stabilisierung; Anwendung von iPSZ; Nicht-klinische Anwendung; Klinische Anwendungen; Ausblick.

    Die vom BMBF geförderte internationale und interdisziplinäre Klausurwoche „Moral Frontiers in Regenerative Medicine pertaining to the Use of Human Embryonic and Induced Pluripotent Stem (iPS) Cells" in Halle (Saale)Anlass der Förderung; Naturwissenschaftlich-medizinischer sowie ELSA-Hintergrund der Klausurwoche; Stammzellen -- Systematik und natürliche Aufgaben; Embryonale Stammzellen -- Rechtliche Limitationen; Adulte Stammzellen -- Tatsächliche Limitationen; iPS-Zellen -- Neue Ansätze für die Regenerative Medizin; ELSA-Fragestellung und Konzept der Klausurwoche

    Methodisches Konzept der KlausurwocheErgebnisse; Öffentliche Einbeziehungs- und Verwertungsstrategie; Fazit; iPS cells and iPS cell-based therapies -- Swiss and UK perspective on definition and regulation; Introduction; A. iPS cells vs. iPS cell-based therapies; B. iPS cells regulation in Switzerland; I. iPS cells definition in Swiss legal acts; II. iPS cell-based therapies definition and regulation in the Swiss legal acts; C. iPS cells regulation in the UK legal system; I. iPS cells definition in the UK legal acts; 2. iPS cell-based therapies regulation in the UK legal acts; D. Conclusions.

    The Ethics of Selling the Promise of Pluripotent Stem CellsIntroduction; Regulation of stem cell interventions in the US; Regulation of stem cell interventions in Australia; The direct-to-consumer marketing of autologous stem cell interventions; Methods; Results; a) Marketed indications; b) The price of PSC/iPSC-based interventions; c) Cell sources, processing and route of administration; d) Claims about safety; e) Claims about efficacy; Discussion; Conclusion; Comparative Law and Co-opetition in Regulatory Norms Formation Pertaining to Human Genetic Modification and Re-Programming.

    A. IntroductionB. Nationalism in the complex cross stitch matrix of regulatory norms; C. Beyond nationalism in the cross stitch matrix; D. Comparative Table as Analytic and Artefact of Relationalities; E. Avoiding the Excesses of Competition through Co-opetition; Why Ethical Qualms over Human Embryonic Stem Cells Are No Longer Relevant: An Analysis of the Evolving Public Discourse and Regulatory Context for Stem Cell Research in Canada; A. Introduction; B. The Stem Cell Controversy in a Comparative Perspective; C. Framing the Stem Cell Policy Debate in Canada; D. The Regulatory Environment.